Your selection
NoneFilter by content type
4-22-2026 - … 0000318154-26-000048 Filing Group Current Reports Issuer AMGEN INC Filing Date 04.22.2026 Document Date 04.22.2026 … 0000318154-26-000048 Filing Group Current Reports Issuer AMGEN INC Filing Date 04.22.2026 Document Date 04.22.2026 …
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
April 22, 2026 - … AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE … THOUSAND OAKS, Calif. , April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of …
4-21-2026 - … 0000318154-26-000045 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.21.2026 Document Date 04.21.2026 … 0000318154-26-000045 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.21.2026 Document Date 04.21.2026 …
4-15-2026 - … 0000318154-26-000040 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.15.2026 Document Date 04.15.2026 … 0000318154-26-000040 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.15.2026 Document Date 04.15.2026 …
4-7-2026 - … 0001193125-26-145596 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.07.2026 Document Date 04.07.2026 … 0001193125-26-145596 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.07.2026 Document Date 04.07.2026 …
4-7-2026 - … 0001193125-26-145588 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.07.2026 Document Date 05.19.2026 … 0001193125-26-145588 Filing Group Proxy Filings Issuer AMGEN INC Filing Date 04.07.2026 Document Date 05.19.2026 …
Thu, 04/30/2026 - 13:30 - … Amgen Q1 2026 Earnings Conference Call Amgen Q1 2026 Earnings Conference Call Event Type Earnings … Amgen Q1 2026 Earnings Conference Call … Amgen Q1 2026 Earnings Conference Call Amgen Q1 2026 Earnings Conference Call Event Type Earnings …
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE
April 6, 2026 - … AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR … LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR … 3 mm THOUSAND OAKS, Calif. , April 6, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline results …
Chairman and CEO Letter and Amgen Inc. 2025 Annual Report
3-31-2026 - … 0000318154-26-000035 Filing Group Annual Filings Issuer AMGEN INC Filing Date 03.31.2026 Document Date 12.31.2025 … 0000318154-26-000035 Filing Group Annual Filings Issuer AMGEN INC Filing Date 03.31.2026 Document Date 12.31.2025 …